Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Walking and thinking at the same time may reveal hidden MS balance issues

NCT ID NCT04090996

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether asking people with multiple sclerosis (MS) to do two things at once — like walking while thinking — can uncover balance problems that standard tests miss. Researchers studied 24 people with mild MS and low disability. The goal was to see if this dual-task approach could detect early signs of instability, which might help doctors start therapy sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dual-task assessment (motor and cognitive tasks performed simultaneously)
What this could lead to
If successful, this could lead to earlier detection of balance issues in MS, helping tailor therapy sooner.
What could go wrong
This is a small, completed observational study with only 24 participants. It does not test a treatment, so it cannot directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Jan 2021

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient aged 18 to 65 years old; * relapsing-remitting MS (RR); * able to hold the station standing 180s without a device assistance; * Expanded Disability Status Scale \<4; * able to give informed consent to participate in this study ; * without any push in the 60 days before the participation in this study (to be clinically stable); * no change in the treatment of MS since at least 2 month. Exclusion Criteria: * acute illness other than MS during the past 60 days; * neurological and psychiatric diseases, except the SEP ; * orthopedic and rheumatological disorders that may affect the market ; * visual acuity \<7/10 for the best eye after correction visual; * patient undergoing psychiatric care;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Neurologie

    Limoges, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.